Advances in Preventive Medicine / 2011 / Article / Tab 5 / Review Article
Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience Table 5 rSBA-MenA, rSBA-MenC, rSBA-MenW-135, and rSBA-MenY antibody response one month [
87 ,
91 ] or 42 days [
90 ] after one dose of MenACWY-TT in toddlers (ATP immunogenicity cohort).
Reference Age group Vaccine
π
%β₯1β:β8 [95% CI] %β₯1β:β128 [95% CI] GMT [95% CI] rSBA-MenA
Knuf et al., 2010 [87 ] 12β14βmonths MenACWY-TT 42 100 [91.6β100] 100 [91.6β100] 5665.2 [4086.0β7854.9]
Vesikari et al., 2011 [90 ] 12β23βmonths MenACWY-TT 354 99.7 [98.4β100] 99.7 [98.4β100] 2205.0 [2007.8β2421.6] MenACWY-TT + MMRV 360 100 [99.0β100] 99.7 [98.5β100] 2085.9 [1905.3β2283.6]
Knuf et al., 2011 [91 ] 12β23βmonths MenACWY-TT 183 98.4 [95.3β99.7] 97.8 [94.5β99.4] 3169.9 [2577.2β3898.8] MenACWY-TT* 178 100 [97.9β100] 100 [97.9β100] 1938.3 [1699.1β2211.2] MenACWY-TT + DTPa-HBV-IPV/Hib 193 100 [98.1β100] 100 [98.1β100] 3152.9 [2752.5β3611.4] rSBA-MenC
Knuf et al., 2010 [87 ] 12β14βmonths MenACWY-TT 42 100 [91.6β100] 95.2 [83.8β99.4] 983.5 [718.7β1345.9] MenC-CRM197 46 97.8 [88.5β100] 87.0 [73.7β95.1] 372.5 [257.7β538.4]
Vesikari et al., 2011 [90 ] 12β23βmonths MenACWY-TT 354 99.7 [98.4β100] 95.8 [93.1β97.6] 477.6 [437.3β521.6] MenACWY-TT + MMRV 357 100 [99.0β100] 94.4 [91.5β96.5] 519.0 [470.9β571.9] MenC-CRM197 121 97.5 [92.9β99.5] 70.2 [61.3β78.2] 212.3 [170.0β265.2]
Knuf et al., 2011 [91 ] 12β23βmonths MenACWY-TT 183 97.3 [93.7β99.1] 94.0 [89.5β97.0] 828.7 [672.4β1021.4] MenACWY-TT* 178 100 [97.9β100] 88.2 [82.5β92.5] 386.0 [333.9β446.2] MenACWY-TT + DTPa-HBV-IPV/Hib 191 100 [98.1β100] 99.0 [96.3β99.9] 879.7 [763.1β1014.0] MenC-CRM197 114 98.2 [93.8β99.8] 89.5 [82.3β94.4] 691.4 [520.8β917.9] rSBA-MenW-135
Knuf et al., 2010 [87 ] 12β14βmonths MenACWY-TT 43 100 [91.8β100] 100 [91.8β100] 3975.2 [3065.7β5154.5]
Vesikari et al., 2011 [90 ] 12β23βmonths MenACWY-TT 354 100 [99.0β100] 99.4 [98.0β99.9] 2681.7 [2453.1β2931.6] MenACWY-TT + MMRV 360 100 [99.0β100] 100 [99.0β100] 2055.8 [1871.0β2258.9]
Knuf et al., 2011 [91 ] 12β23βmonths MenACWY-TT 186 98.4 [95.4β99.7] 96.8 [93.1β98.8] 4022.3 [3269.2β4948.8] MenACWY-TT* 179 100 [98.0β100] 99.4 [96.9β100] 2466.4 [2175.4β2796.4] MenACWY-TT + DTPa-HBV-IPV/Hib 193 100 [98.1β100] 100 [98.1β100] 4147.0 [3670.1β4685.8] rSBA-MenY
Knuf et al., 2010 [87 ] 12β14βmonths MenACWY-TT 42 100 [91.6β100] 100 [91.6β100] 2295.1 [1701.5β3095.8]
Vesikari et al., 2011 [90 ] 12β23βmonths MenACWY-TT 354 100 [99.0β100] 99.7 [98.4β100] 2729.4 [2472.7β3012.8] MenACWY-TT + MMRV 359 100 [99.0β100] 99.7 [98.5β100] 2282.4 [2051.3β2539.5]
Knuf et al., 2011 [91 ] 12β23βmonths MenACWY-TT 185 97.3 [93.8β99.1] 96.2 [92.4β98.5] 3167.7 [2521.9β3978.9] MenACWY-TT* 179 99.4 [96.9β100] 99.4 [96.9β100] 2446.9 [2088.5β2866.8] MenACWY-TT + DTPa-HBV-IPV/Hib 192 100 [98.1β100] 100 [98.1β100] 3461.8 [2990.1β4007.9]
π
: numbers of subjects with available data, %: percentage of subjects with titre within the specified range, 95% CI: 95% confidence interval, GMT: Geometric Mean Titre, *MenACWY-TT given one month after DTPa-HBV-IPV/Hib vaccine, Results of this table were previously published [87 , 90 , 91 ].